Related Experiment Video
Updated: Feb 22, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators
Hannah M Kansen1, Patrick F van Rheenen, Roderick H J Houwen
1*Department of Paediatric Gastroenterology, University Medical Centre-Wilhelmina Children's Hospital, Utrecht†Department of Paediatric Gastroenterology, University Medical Centre Groningen, University of Groningen, Groningen‡Department of Paediatric Gastroenterology, Maxima Medical Centre, Veldhoven§Department of Paediatric Gastroenterology, Radboud University Medical Centre-Amalia Children's Hospital, Nijmegen||Department of Paediatric Gastroenterology, Emma Children's Hospital, Academic Medical Center, Amsterdam¶Department of Paediatric Gastroenterology, Erasmus Medical Centre-Sophia Children's Hospital, Rotterdam, The Netherlands.
Objectives:
To evaluate the effect of immunomodulators on formation of antibodies to infliximab (ATI) in paediatric patients with Crohn disease (CD) and the association of ATI and loss of response.
Methods:
Retrospective multicentre observational study (January 2009-December 2014) among Dutch children with CD treated with infliximab (IFX). ATI formation was analysed with Chi-square test and time-to-ATI formation with Kaplan-Meier and log-rank test.
Results:
A total of 229 children were identified. ATIs were measured in 162 patients (70.7%) and 25 (15%) developed ATIs: 6 of 62 (10%) on continuous combined immunosuppression (CCI), 11 of 81 (14%) on early combined immunosuppression (ECI), and 8 of 19 (42%) on IFX monotherapy. ATI formation was higher in patients on IFX monotherapy compared to CCI (P = 0.003) and ECI (P = 0.008), whereas no significant difference was found between CCI and ECI. Sixteen out of 25 patients (64%) with ATIs had loss of response, compared with 32 of 137 patients (19%) without ATIs (P < 0.00002, log rank 0.02). Among patients treated with ECI, 10 of 55 (18%) developed ATIs within the first 12 months, compared to 1 of 26 (4%) after more than 12 months.
Conclusions:
In children with CD combination therapy is associated with significant reduction of antibody formation and prolonged effectivity compared to IFX monotherapy. ECI for at least 12 months, followed by IFX monotherapy, may be an equally effective alternative to CCI.
More Related Videos
07:51Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pharmacokinetics in Pediatric Patients: Drug Excretion